<HTML>
<HEAD>
<TITLE>August 22, 2018 S-8 DOC</TITLE>
</HEAD>

<BODY LINK="#0000ff" VLINK="#800080" BGCOLOR="#ffffff">
<font FACE="Times New Roman" SIZE="2">


<DIV align=left>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">
</DIV>

<FONT SIZE=2><P ALIGN="CENTER">As filed with the Securities and Exchange Commission on August 22, 2018</P>

<P ALIGN="RIGHT">Registration&nbsp;No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>




<B><FONT SIZE=3><P ALIGN="CENTER">UNITED STATES <BR>
                  SECURITIES AND EXCHANGE COMMISSION <BR>
</FONT>                  Washington, D.C. 20549 </P></B>

<HR WIDTH="25%" ALIGN="CENTER">

<B><FONT SIZE=3><P ALIGN="CENTER">FORM S-8 <BR>
                  REGISTRATION STATEMENT <BR>
</FONT><I>                  UNDER <BR>
                  THE SECURITIES ACT OF 1933 </I></B>&nbsp;</P>

<HR WIDTH="25%" ALIGN="CENTER">

<B><FONT SIZE=3><P ALIGN="CENTER">Pernix Therapeutics Holdings, Inc.<BR>
</FONT><FONT SIZE=2>                  (Exact name of registrant as specified in its charter)</P>
</B></FONT>



<P ALIGN="CENTER"><CENTER><TABLE CELLSPACING=0 BORDER=0 WIDTH=624>
<TR><TD WIDTH="51%" VALIGN="MIDDLE">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="48%" VALIGN="MIDDLE">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<B><FONT SIZE=2><P ALIGN="CENTER">Maryland</B></FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="48%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="CENTER">33-0724736</B></FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="CENTER">(State or other jurisdiction of<BR>
incorporation or organization)</B></FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM">
<FONT SIZE=1><P>&nbsp;</FONT></TD>
<TD WIDTH="48%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="CENTER">(I.R.S. Employer<BR>
Identification No.)</B></FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="MIDDLE" HEIGHT=16><P></P></TD>
<TD WIDTH="49%" VALIGN="MIDDLE" COLSPAN=2 HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="CENTER">10 North Park Place, Suite 201<BR>
                  Morristown, New Jersey </B></FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="48%" VALIGN="BOTTOM">
<B><FONT SIZE=1><P ALIGN="CENTER">07960</B></FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="CENTER">(Address of Principal Executive Offices)</B></FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM">
<FONT SIZE=1><P>&nbsp;</FONT></TD>
<TD WIDTH="48%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="CENTER">(Zip Code)</B></FONT></TD>
</TR>
</TABLE>
</CENTER></P>

<B><FONT SIZE=2><P ALIGN="CENTER">PERNIX THERAPEUTICS HOLDINGS, INC. 2017 OMNIBUS INCENTIVE PLAN<BR>
</FONT><FONT SIZE=1>(Full title of the plan) </P>
<P ALIGN="CENTER">&nbsp;</P>
</FONT><FONT SIZE=1><P ALIGN="CENTER">John A. Sedor<BR>
                  Chief Executive Officer<BR>
                  10 North Park Place, Suite 201<BR>
                  Morristown, New Jersey 07960<BR>
</FONT><FONT SIZE=1>                  (Name and address of agent for service)</P>
</FONT><FONT SIZE=1><P ALIGN="CENTER">(800) 793-2145</FONT><FONT SIZE=2> <BR>
</FONT><FONT SIZE=1>                  (Telephone number, including area code, of agent for service) </P>
</B></FONT>

<HR WIDTH="25%" ALIGN="CENTER">

<B><FONT SIZE=1><P ALIGN="CENTER">With Copies to:</P>
<P ALIGN="CENTER">Kenneth R. Pi&ntilde;a<BR>
                  Senior Vice President, Chief Legal and Compliance Officer <BR>
                  and Corporate Secretary<BR>
                  10 North Park Place, Suite 201<BR>
                  Morristown, New Jersey 07960<BR>
                  (800) 793-2145</P>
<P ALIGN="CENTER">and</P>
<P ALIGN="CENTER">Steven J. Abrams<BR>
                  Hogan Lovells US LLP<BR>
                  1735 Market Street, 23rd Floor<BR>
                  Philadelphia, PA 19103<BR>
                  (267) 675-4600</P>
</B></FONT>

<FONT SIZE=2><P>&nbsp;</P>

<HR WIDTH="25%" ALIGN="CENTER">

<P>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the
definitions of &quot;large accelerated filer,&quot; &quot;accelerated filer,&quot; &quot;smaller reporting company&quot; and &quot;emerging growth company&quot; in Rule 12b-2 of the
Exchange Act (Check one):</P></FONT>

<P ALIGN="CENTER"><CENTER><TABLE CELLSPACING=0 BORDER=0 CELLPADDING=0 WIDTH=85%>
<TR><TD WIDTH="22%" VALIGN="BOTTOM">
<FONT SIZE=2><P>Large accelerated filer</FONT></TD>
<TD WIDTH="46%" VALIGN="BOTTOM">
<FONT FACE="MS Gothic" LANG="JA" SIZE=2><P>&#9744;</FONT></TD>
<TD WIDTH="28%" VALIGN="BOTTOM">
<FONT SIZE=2><P>Accelerated filer</FONT></TD>
<TD WIDTH="4%" VALIGN="BOTTOM">
<FONT FACE="MS Gothic" LANG="JA" SIZE=2><P>&#9744;</FONT></TD>
</TR>
<TR><TD WIDTH="22%" VALIGN="BOTTOM">
<FONT SIZE=2><P>Non-accelerated filer</FONT></TD>
<TD WIDTH="46%" VALIGN="BOTTOM">
<FONT FACE="MS Gothic" LANG="JA" SIZE=2><P>&#9744;</FONT><FONT SIZE=2>&#9;(Do not check if a smaller reporting company)</FONT></TD>
<TD WIDTH="28%" VALIGN="BOTTOM">
<FONT SIZE=2><P>Smaller reporting company</FONT></TD>
<TD WIDTH="4%" VALIGN="BOTTOM">
<FONT FACE="MS Gothic" LANG="JA" SIZE=2><P>&#9746;</FONT></TD>
</TR>
<TR><TD WIDTH="22%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="46%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="28%" VALIGN="BOTTOM">
<FONT SIZE=2><P>Emerging growth company</FONT></TD>
<TD WIDTH="4%" VALIGN="BOTTOM">
<FONT FACE="MS Gothic" LANG="JA" SIZE=2><P>&#9744;</FONT></TD>
</TR>
</TABLE>
</CENTER></P>

<HR WIDTH="25%" ALIGN="CENTER">


<B><FONT SIZE=2><P ALIGN="CENTER">CALCULATION OF REGISTRATION FEE </P></B>

<P ALIGN="CENTER"><CENTER><TABLE BORDER=0 CELLSPACING=1 BORDERCOLOR="#000000" WIDTH=85%>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="44%" VALIGN="BOTTOM">
<B><FONT SIZE=1><P ALIGN="CENTER">Title of Securities<BR>
to be Registered</B></FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM">
<FONT SIZE=1><P>&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="13%" VALIGN="BOTTOM">
<B><FONT SIZE=1><P ALIGN="CENTER">Amount<BR>
to&nbsp;be<BR>
Registered&nbsp;(1)</B></FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM">
<FONT SIZE=1><P>&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="13%" VALIGN="BOTTOM">
<B><FONT SIZE=1><P ALIGN="CENTER">Proposed<BR>
Maximum<BR>
Offering&nbsp;Price<BR>
Per&nbsp;Share (2)</B></FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM">
<FONT SIZE=1><P>&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="16%" VALIGN="BOTTOM">
<B><FONT SIZE=1><P ALIGN="CENTER">Proposed<BR>
Maximum<BR>
Aggregate<BR>
Offering&nbsp;Price</B></FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM">
<FONT SIZE=1><P>&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="12%" VALIGN="BOTTOM">
<B><FONT SIZE=1><P ALIGN="CENTER">Amount&nbsp;of<BR>
Registration&nbsp;Fee</B></FONT></TD>
</TR>
<TR><TD WIDTH="44%" VALIGN="BOTTOM">
<FONT SIZE=1><P>Common Stock, par value $0.01 per share
</FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="CENTER">600,000</FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM">
<FONT SIZE=1><P>&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="CENTER">$1.45</FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM">
<FONT SIZE=1><P>&nbsp;</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="CENTER">$870,000</FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM">
<FONT SIZE=1><P>&nbsp;</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="CENTER">$108.32</FONT></TD>
</TR>
</TABLE>
</CENTER></P>

<HR WIDTH="98%" ALIGN="CENTER">


<TABLE CELLSPACING=0 BORDER=0 WIDTH=85%>
<TR><TD WIDTH="4%" VALIGN="TOP" HEIGHT=25>
<FONT SIZE=2><P> (1)</FONT></TD>
<TD WIDTH="96%" VALIGN="TOP" HEIGHT=25>
<FONT SIZE=2><P>This registration statement covers 600,000 shares of common stock, par value $0.01 per share (the &quot;Common Stock&quot;) of Pernix Therapeutics Holdings, Inc., a
Maryland corporation (the &quot;Registrant&quot;), issuable pursuant to the Registrant's 2017 Omnibus Incentive Plan, as amended (the &quot;Plan&quot;). Pursuant to Rule 416 under the
Securities Act of 1933, as amended, this Registration Statement shall be deemed to cover any additional shares of Common Stock which become issuable under the Plan pursuant to this
Registration Statement by reason of any stock dividend, stock split, recapitalization or any other similar transactions.</P>
<P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="4%" VALIGN="TOP" HEIGHT=40>
<FONT SIZE=2><P>(2)</FONT></TD>
<TD WIDTH="96%" VALIGN="TOP" HEIGHT=40>
<FONT SIZE=2><P>Estimated solely for the purpose of calculating the registration fee under Rule 457(c) and (h) of the Securities Act of 1933, as amended, on the basis of the average of the
high and low sales price per share of common stock on August 20, 2018, as reported on the Nasdaq Global Market.</FONT></TD>
</TR>
</TABLE>

<P> &nbsp; </P>

<FONT SIZE=2>
<DIV align=left>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">
</DIV>

<P style="PAGE-BREAK-BEFORE: always" align=left>




<B><P ALIGN="CENTER">EXPLANATORY NOTE</P>

</B><P>This Registration Statement is being filed for the purpose of registering additional shares of common stock, par value $0.01 per share (the &quot;Common Stock&quot;) of Pernix
Therapeutics Holdings, Inc. (the &quot;Registrant&quot;) in connection with the Pernix Therapeutics Holdings, Inc. 2017 Omnibus Incentive Plan, as amended (the &quot;Plan&quot;) for which
a Registration Statement on Form&nbsp;S-8 relating to the Plan is effective. This Registration Statement on Form S-8 (the &quot;Registration Statement&quot;) registers an additional 600,000
shares of Common Stock of the Registrant to be issued pursuant to the Plan. The contents of the previous Registration Statement on Form&nbsp;S-8 filed by the Registrant with the Securities
and Exchange Commission (the &quot;SEC&quot;) for the Plan on November 20, 2017 (File No.&nbsp;333-221678), to the extent not otherwise amended or superseded by the contents
hereof, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form&nbsp;S-8.</P>

<B><P ALIGN="CENTER">PART II</P>
</B>
<B><P ALIGN="CENTER">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</P></B>


<B><P>Item 3.&#9;&#9;Incorporation of Documents by Reference. </P></B>

<P>The following documents filed by the Registrant are incorporated herein by reference (other than, in each case, documents or information deemed to have been furnished and not filed in
accordance with SEC rules): </P>

<DIR>

<TABLE CELLSPACING=4 BORDER=0 WIDTH=95%>
<TR>
<TD WIDTH="3%" VALIGN="TOP">
<FONT SIZE=2><P>
(a)
</FONT></TD>
<TD WIDTH="97%" VALIGN="TOP">
<FONT SIZE=2><P>
The Registrant's Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 8, 2018;
</FONT></TD>
</TR>
<TR>
<TD WIDTH="3%" VALIGN="TOP">
<FONT SIZE=2><P>
(b)
</FONT></TD>
<TD WIDTH="97%" VALIGN="TOP">
<FONT SIZE=2><P>
The Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 filed with the SEC on May 10, 2018;
</FONT></TD>
</TR>
<TR>
<TD WIDTH="3%" VALIGN="TOP">
<FONT SIZE=2><P>
(c)
</FONT></TD>
<TD WIDTH="97%" VALIGN="TOP">
<FONT SIZE=2><P>
The Registrant's Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 filed with the SEC on August 9, 2018;
</FONT></TD>
</TR>
<TR>
<TD WIDTH="3%" VALIGN="TOP">
<FONT SIZE=2><P>
(d)
</FONT></TD>
<TD WIDTH="97%" VALIGN="TOP">
<FONT SIZE=2><P>
The Registrant's Definitive Proxy Statement on Schedule 14A filed with the SEC on April 9, 2018, to the extent incorporated by reference into the Registrant's Annual Report on Form 10-K
for the year ended December 31, 2017;
</FONT></TD>
</TR>
<TR>
<TD WIDTH="3%" VALIGN="TOP">
<FONT SIZE=2><P>
(e)
</FONT></TD>
<TD WIDTH="97%" VALIGN="TOP">
<FONT SIZE=2><P>
The Registrant's Current Reports on Form 8-K filed with the SEC on January 5, 2018, January 29, 2018, February 6, 2018, February 20, 2018, February 28, 2018, March 5, 2018, March
27, 2018, April 24, 2018, May 22, 2018, June 22, 2018, July 31, 2018 and August 1, 2018; and
</FONT></TD>
</TR>
<TR>
<TD WIDTH="3%" VALIGN="TOP">
<FONT SIZE=2><P>
(f)
</FONT></TD>
<TD WIDTH="97%" VALIGN="TOP">
<FONT SIZE=2><P>
The description of the common stock contained in the Registrant's Current Report on Form 8-A filed with the SEC on February 7, 1997, as amended by that certain Form 8-A filed with the
SEC on March 15, 2010, including any amendment or report filed for the purpose of updating such description.
</FONT></TD>
</TR>
</TABLE>

</DIR>

<P>All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective
amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein
and to be part hereof from the date of filing of such reports and documents, except for the documents, or portions thereof, that are "furnished" rather than filed with the SEC.</P>

<P>For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or
superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or
supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration
Statement.&nbsp;</P>


<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><P>Item 8.&#9;&#9;Exhibits.</P>
</B>



<B><P ALIGN="CENTER">Exhibit Index</P>
</B>

<TABLE CELLSPACING=0 BORDER=0 WIDTH=95%>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="8%" VALIGN="BOTTOM" HEIGHT=25>
<B><FONT SIZE=2><P>Exhibit<BR>
Number</B></FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM" HEIGHT=25>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="87%" VALIGN="BOTTOM" HEIGHT=25>
<B><FONT SIZE=2><P>Description</B></FONT></TD>
</TR>
<TR><TD WIDTH="8%" VALIGN="MIDDLE" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="92%" VALIGN="MIDDLE" COLSPAN=2 HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="8%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P><A HREF="exh5-1.htm">5.1</A></FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="87%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P>Opinion of Hogan Lovells US LLP (filed herewith).</FONT></TD>
</TR>
<TR><TD WIDTH="8%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1024126/000113626118000139/exh10-1.htm">10.1</A></FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="87%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P>
Pernix Therapeutics Holdings, Inc. 2017 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K,
filed May 22, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="8%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P><A HREF="exh23-1.htm">23.1</A></FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM" HEIGHT=16><P></P></TD>
<TD WIDTH="87%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P>Consent of Cherry Bekaert LLP, Independent Registered Public Accounting Firm (filed herewith).</FONT></TD>
</TR>
<TR><TD WIDTH="8%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P><A HREF="exh5-1.htm">23.2</A></FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="87%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P>Consent of Hogan Lovells US LLP (included in Exhibit 5.1).</FONT></TD>
</TR>
<TR><TD WIDTH="8%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P>24.1</FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="87%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P>Power of Attorney (included in signature page to this Registration Statement).</FONT></TD>
</TR>
</TABLE>



<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>


<B><P ALIGN="CENTER">SIGNATURES</P></B>

<P>Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on
Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in in the town of Morristown, the State of New Jersey, on
this 22<SUP>nd</SUP> day of August, 2018.</P>

<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>



<TABLE CELLSPACING=0 BORDER=0 WIDTH=35%>
<TR><TD WIDTH="8%" VALIGN="MIDDLE">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="91%" VALIGN="MIDDLE">&nbsp;</TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=3>
<B><FONT SIZE=2><P>PERNIX THERAPEUTICS HOLDINGS, INC.</B></FONT></TD>
</TR>
<TR><TD WIDTH="8%" VALIGN="MIDDLE" HEIGHT=16><P></P></TD>
<TD WIDTH="92%" VALIGN="MIDDLE" COLSPAN=2 HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="8%" VALIGN="TOP">
<FONT SIZE=2><P>By:</FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="91%" VALIGN="BOTTOM">
<FONT SIZE=2><P>/s/ John A. Sedor</FONT></TD>
</TR>
<TR><TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="91%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;John A. Sedor</FONT></TD>
</TR>
<TR><TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="91%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer and Chairman</FONT></TD>
</TR>
</TABLE>

</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>



<B><P ALIGN="CENTER">POWER OF ATTORNEY</P>
</B>
<P>We, the undersigned officers and directors of Pernix Therapeutics Holdings, Inc., hereby severally constitute and appoint John A. Sedor and Kenneth R. Pi&ntilde;a, and each of them
singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8
filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and
directors to enable Pernix Therapeutics Holdings, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange
Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments
thereto.</P>

<P>Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities held on the dates indicated.</P>

<TABLE BORDER=0 CELLSPACING=1 BORDERCOLOR="#000000" WIDTH=85%>
<TR><TD WIDTH="33%" VALIGN="MIDDLE" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="32%" VALIGN="MIDDLE" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="33%" VALIGN="BOTTOM" HEIGHT=14>
<B><FONT SIZE=2><P ALIGN="CENTER">Signature</B></FONT></TD>
<TD WIDTH="2%" VALIGN="BOTTOM" HEIGHT=14>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="32%" VALIGN="BOTTOM" HEIGHT=14>
<B><FONT SIZE=2><P ALIGN="CENTER">Title</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=14>
<B><FONT SIZE=2><P ALIGN="CENTER">Date</B></FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="MIDDLE" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="35%" VALIGN="MIDDLE" COLSPAN=3 HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="33%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">/s/ John A. Sedor</FONT></TD>
<TD WIDTH="2%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Chairman and Chief Executive Officer</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=16>
<FONT SIZE=2><P ALIGN="RIGHT">August 22, 2018</FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">John A. Sedor</FONT></TD>
<TD WIDTH="2%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">(Principal Executive Officer)</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="MIDDLE" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="35%" VALIGN="MIDDLE" COLSPAN=3 HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="33%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">/s/ Angus Smith </FONT></TD>
<TD WIDTH="2%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Senior Vice President, Chief Business Officer and Principal Financial Officer</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=16>
<FONT SIZE=2><P ALIGN="RIGHT">August 22, 2018</FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Angus Smith</FONT></TD>
<TD WIDTH="2%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">(Principal Financial Officer)</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="MIDDLE" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="35%" VALIGN="MIDDLE" COLSPAN=3 HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="33%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">/s/ Glenn Whaley</FONT></TD>
<TD WIDTH="2%" VALIGN="BOTTOM" HEIGHT=30>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=30>
<FONT SIZE=2><P ALIGN="CENTER">Vice President of Finance, Principal Accounting Officer and Controller</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=30>
<FONT SIZE=2><P ALIGN="RIGHT">August 22, 2018</FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Glenn Whaley&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">(Principal Accounting Officer)</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="MIDDLE" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="35%" VALIGN="MIDDLE" COLSPAN=3 HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="33%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">/s/ Dennis H. Langer</FONT></TD>
<TD WIDTH="2%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Director</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=16>
<FONT SIZE=2><P ALIGN="RIGHT">August 22, 2018</FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Dennis H. Langer</FONT></TD>
<TD WIDTH="2%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="MIDDLE" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="35%" VALIGN="MIDDLE" COLSPAN=3 HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="33%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">/s/ John R. Leone</FONT></TD>
<TD WIDTH="2%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Director</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=16>
<FONT SIZE=2><P ALIGN="RIGHT">August 22, 2018</FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">John R. Leone </FONT></TD>
<TD WIDTH="2%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="MIDDLE" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="35%" VALIGN="MIDDLE" COLSPAN=3 HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="33%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">/s/ Gabriel Leung</FONT></TD>
<TD WIDTH="2%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Director</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=16>
<FONT SIZE=2><P ALIGN="RIGHT">August 22, 2018</FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Gabriel Leung</FONT></TD>
<TD WIDTH="2%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="MIDDLE" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="35%" VALIGN="MIDDLE" COLSPAN=3 HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="33%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">/s/ Douglas J. Swirsky</FONT></TD>
<TD WIDTH="2%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Director</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=16>
<FONT SIZE=2><P ALIGN="RIGHT">August 22, 2018</FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Douglas J. Swirsky</FONT></TD>
<TD WIDTH="2%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
</TABLE>
</CENTER></P>



<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P> &nbsp; </P>




</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "s8body.htm", "description": "S-8", "secsgml_size_bytes": 28170}]
{"company-data": {"conformed-name": "PERNIX THERAPEUTICS HOLDINGS, INC.", "cik": "0001024126", "assigned-sic": "2834", "irs-number": "330724736", "state-of-incorporation": "MD", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-226973", "film-number": "181033034"}, "business-address": {"street1": "10 NORTH PARK PLACE", "street2": "SUITE 201", "city": "MORRISTOWN", "state": "NJ", "zip": "07960", "phone": "(862) 260-8457"}, "mail-address": {"street1": "10 NORTH PARK PLACE", "street2": "SUITE 201", "city": "MORRISTOWN", "state": "NJ", "zip": "07960"}, "former-company": {"former-conformed-name": "GOLF TRUST OF AMERICA INC", "date-changed": "19961002"}}
August 22, 2018 S-8 DOC
As filed with the Securities and Exchange Commission on August 22, 2018
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Pernix Therapeutics Holdings, Inc.
(Exact name of registrant as specified in its charter)
Maryland
33-0724736
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
10 North Park Place, Suite 201
Morristown, New Jersey
07960
(Address of Principal Executive Offices)
(Zip Code)
PERNIX THERAPEUTICS HOLDINGS, INC. 2017 OMNIBUS INCENTIVE PLAN
(Full title of the plan)
John A. Sedor
Chief Executive Officer
10 North Park Place, Suite 201
Morristown, New Jersey 07960
(Name and address of agent for service)
(800) 793-2145
(Telephone number, including area code, of agent for service)
With Copies to:
Kenneth R. Piña
Senior Vice President, Chief Legal and Compliance Officer
and Corporate Secretary
10 North Park Place, Suite 201
Morristown, New Jersey 07960
(800) 793-2145
and
Steven J. Abrams
Hogan Lovells US LLP
1735 Market Street, 23rd Floor
Philadelphia, PA 19103
(267) 675-4600
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the
definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the
Exchange Act (Check one):
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☐
(Do not check if a smaller reporting company)
Smaller reporting company
☒
Emerging growth company
☐
CALCULATION OF REGISTRATION FEE
Title of Securities
to be Registered
Amount
to be
Registered (1)
Proposed
Maximum
Offering Price
Per Share (2)
Proposed
Maximum
Aggregate
Offering Price
Amount of
Registration Fee
Common Stock, par value $0.01 per share
600,000
$1.45
$870,000
$108.32
(1)
This registration statement covers 600,000 shares of common stock, par value $0.01 per share (the "Common Stock") of Pernix Therapeutics Holdings, Inc., a
Maryland corporation (the "Registrant"), issuable pursuant to the Registrant's 2017 Omnibus Incentive Plan, as amended (the "Plan"). Pursuant to Rule 416 under the
Securities Act of 1933, as amended, this Registration Statement shall be deemed to cover any additional shares of Common Stock which become issuable under the Plan pursuant to this
Registration Statement by reason of any stock dividend, stock split, recapitalization or any other similar transactions.
(2)
Estimated solely for the purpose of calculating the registration fee under Rule 457(c) and (h) of the Securities Act of 1933, as amended, on the basis of the average of the
high and low sales price per share of common stock on August 20, 2018, as reported on the Nasdaq Global Market.
EXPLANATORY NOTE
This Registration Statement is being filed for the purpose of registering additional shares of common stock, par value $0.01 per share (the "Common Stock") of Pernix
Therapeutics Holdings, Inc. (the "Registrant") in connection with the Pernix Therapeutics Holdings, Inc. 2017 Omnibus Incentive Plan, as amended (the "Plan") for which
a Registration Statement on Form S-8 relating to the Plan is effective. This Registration Statement on Form S-8 (the "Registration Statement") registers an additional 600,000
shares of Common Stock of the Registrant to be issued pursuant to the Plan. The contents of the previous Registration Statement on Form S-8 filed by the Registrant with the Securities
and Exchange Commission (the "SEC") for the Plan on November 20, 2017 (File No. 333-221678), to the extent not otherwise amended or superseded by the contents
hereof, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3.		Incorporation of Documents by Reference.
The following documents filed by the Registrant are incorporated herein by reference (other than, in each case, documents or information deemed to have been furnished and not filed in
accordance with SEC rules):
(a)
The Registrant's Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 8, 2018;
(b)
The Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 filed with the SEC on May 10, 2018;
(c)
The Registrant's Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 filed with the SEC on August 9, 2018;
(d)
The Registrant's Definitive Proxy Statement on Schedule 14A filed with the SEC on April 9, 2018, to the extent incorporated by reference into the Registrant's Annual Report on Form 10-K
for the year ended December 31, 2017;
(e)
The Registrant's Current Reports on Form 8-K filed with the SEC on January 5, 2018, January 29, 2018, February 6, 2018, February 20, 2018, February 28, 2018, March 5, 2018, March
27, 2018, April 24, 2018, May 22, 2018, June 22, 2018, July 31, 2018 and August 1, 2018; and
(f)
The description of the common stock contained in the Registrant's Current Report on Form 8-A filed with the SEC on February 7, 1997, as amended by that certain Form 8-A filed with the
SEC on March 15, 2010, including any amendment or report filed for the purpose of updating such description.
All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective
amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein
and to be part hereof from the date of filing of such reports and documents, except for the documents, or portions thereof, that are "furnished" rather than filed with the SEC.
For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or
superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or
supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration
Statement.
Item 8.		Exhibits.
Exhibit Index
Exhibit
Number
Description
5.1
Opinion of Hogan Lovells US LLP (filed herewith).
10.1
Pernix Therapeutics Holdings, Inc. 2017 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K,
filed May 22, 2018).
23.1
Consent of Cherry Bekaert LLP, Independent Registered Public Accounting Firm (filed herewith).
23.2
Consent of Hogan Lovells US LLP (included in Exhibit 5.1).
24.1
Power of Attorney (included in signature page to this Registration Statement).
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on
Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in in the town of Morristown, the State of New Jersey, on
this 22
nd
day of August, 2018.
PERNIX THERAPEUTICS HOLDINGS, INC.
By:
/s/ John A. Sedor
John A. Sedor
Chief Executive Officer and Chairman
POWER OF ATTORNEY
We, the undersigned officers and directors of Pernix Therapeutics Holdings, Inc., hereby severally constitute and appoint John A. Sedor and Kenneth R. Piña, and each of them
singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8
filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and
directors to enable Pernix Therapeutics Holdings, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange
Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments
thereto.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities held on the dates indicated.
Signature
Title
Date
/s/ John A. Sedor
Chairman and Chief Executive Officer
August 22, 2018
John A. Sedor
(Principal Executive Officer)
/s/ Angus Smith
Senior Vice President, Chief Business Officer and Principal Financial Officer
August 22, 2018
Angus Smith
(Principal Financial Officer)
/s/ Glenn Whaley
Vice President of Finance, Principal Accounting Officer and Controller
August 22, 2018
Glenn Whaley
(Principal Accounting Officer)
/s/ Dennis H. Langer
Director
August 22, 2018
Dennis H. Langer
/s/ John R. Leone
Director
August 22, 2018
John R. Leone
/s/ Gabriel Leung
Director
August 22, 2018
Gabriel Leung
/s/ Douglas J. Swirsky
Director
August 22, 2018
Douglas J. Swirsky